Mipomersen, an antisense apolipoprotein B synthesis inhibitor

Bibliography

• Davidson MH. Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep 2009;11:67-70
   PubMed Web of Science ®Google Scholar
• Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci 2005;42:515-45
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, , editors, The metabolic and molecular bases of inherited disease. 8th edition. McGraw-Hill, New York; 2001. p. 2863-913
   Google Scholar
• Crooke RM. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 2005;5:907-17
   PubMed Web of Science ®Google Scholar
• Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opin Pharmacother 2010;11:2569-72
   PubMed Web of Science ®Google Scholar
• Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep 2010;12:58-65
   PubMed Web of Science ®Google Scholar
• Visser ME, Kastelein JJ, Stroes ES. Apolipoprotein B synthesis inhibition: results from clinical trials. Curr Opin Lipidol 2010;21:319-23
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
   PubMed Web of Science ®Google Scholar
• Thompson GR, Maher VM, Matthews S, Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345(8953):811-6
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-7
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J, Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Geary RS, Watanabe TA, Truong L, Pharmacokinetic properties of 2c-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001;296:890-7
   PubMed Web of Science ®Google Scholar
• Yu RZ, Geary RS, Monteith DK, Tissue disposition of 2c-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci 2004;93:48-59
   PubMed Web of Science ®Google Scholar
• Crooke RM, Graham MJ, Lemonidis KM, An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46:872-84
   PubMed Web of Science ®Google Scholar
• Altmann KH, Fabbro D, Dean NM, Second-generation antisense oligonucleotides: structure-activity relationships and the design of improved signal-transduction inhibitors. Biochem Soc Trans 1996;24:630-7
   PubMed Web of Science ®Google Scholar
• Wu H, MacLeod AR, Lima WF, Crooke ST. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem 1998;273:2532-42
   PubMed Web of Science ®Google Scholar
• Yu RZ, Lemonidis KM, Graham MJ, Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009;77:910-19
   PubMed Web of Science ®Google Scholar
• Yu RZ, Kim TW, Hong A, Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007;35:460-8
   PubMed Web of Science ®Google Scholar
• Yu RZ, Geary RS, Flaim JD, Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2c-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009;48:39-50
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Wedel MK, Baker BF, Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006;114:1729-35
   PubMed Web of Science ®Google Scholar
• Akdim F, Visser ME, Tribble DL, Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010;105:1413-19
   PubMed Web of Science ®Google Scholar
• Akdim F, Stroes ES, Sijbrands E, Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010;55:1611-18
   PubMed Web of Science ®Google Scholar
• Visser ME, Akdim F, Tribble DL, Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010;51:1057-62
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:998-1006
   PubMed Web of Science ®Google Scholar
• Data from mipomersen phase 3 trial in heFH patients presented at ESC. Carlsbad, CA: ISIS Pharmaceuticals, 1st September 2010. Available from: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1465238&highlight= [Last accessed 14 December 2010]
   Google Scholar
• Genzyme and ISIS report results of two phase 3 trials of mipomersen. Carlsbad, CA: ISIS Pharmaceuticals, 4th August 2010, Available from: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1456209&highlight= [Last accessed 14 December 2010]
   Google Scholar
• Kling J. Safety signal dampens reception for mipomersen antisense. Nat Biotechnol 2010;28:295-7
   PubMed Web of Science ®Google Scholar
• Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci 2005;62:1372-13788
   PubMed Web of Science ®Google Scholar
• Kane JP, Havel RJ. Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, , editors, The metabolic and molecular bases of inherited disease. 8th edition. McGraw-Hill, New York; 2001. p. 2717-52
   Google Scholar
• Burnett JR, Watts GF. MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises? Expert Opin Ther Targets 2007;11:181-9
   PubMed Web of Science ®Google Scholar
• Samaha FF, McKenney J, Bloedon LT, Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497-505
   PubMedGoogle Scholar